GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd (SGX:T14) » Definitions » Scaled Net Operating Assets

Tianjin Pharmaceutical Da Ren Tang Group (SGX:T14) Scaled Net Operating Assets : 0.54 (As of Sep. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Tianjin Pharmaceutical Da Ren Tang Group Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tianjin Pharmaceutical Da Ren Tang Group's operating assets for the quarter that ended in Sep. 2024 was $1,345 Mil. Tianjin Pharmaceutical Da Ren Tang Group's operating liabilities for the quarter that ended in Sep. 2024 was $457 Mil. Tianjin Pharmaceutical Da Ren Tang Group's Total Assets for the quarter that ended in Jun. 2024 was $1,640 Mil. Therefore, Tianjin Pharmaceutical Da Ren Tang Group's scaled net operating assets (SNOA) for the quarter that ended in Sep. 2024 was 0.54.


Tianjin Pharmaceutical Da Ren Tang Group Scaled Net Operating Assets Historical Data

The historical data trend for Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tianjin Pharmaceutical Da Ren Tang Group Scaled Net Operating Assets Chart

Tianjin Pharmaceutical Da Ren Tang Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.56 0.55 0.53 0.40 0.47

Tianjin Pharmaceutical Da Ren Tang Group Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.50 0.48 0.50 0.35 0.54

Competitive Comparison of Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets

For the Drug Manufacturers - Specialty & Generic subindustry, Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets falls into.



Tianjin Pharmaceutical Da Ren Tang Group Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(1135.108-455.971)/1456.887
=0.47

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1432.747 - 297.639
=1135.108

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=502.068 - 34.142 - 11.955
=455.971

Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets (SNOA) for the quarter that ended in Sep. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Sep. 2024 )
=(Operating Assets (Q: Sep. 2024 )-Operating Liabilities (Q: Sep. 2024 ))/Total Assets (Q: Jun. 2024 )
=(1344.671-456.897)/1640.468
=0.54

where

Operating Assets(Q: Sep. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1550.244 - 205.573
=1344.671

Operating Liabilities(Q: Sep. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=638.162 - 30.708 - 150.557
=456.897

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Tianjin Pharmaceutical Da Ren Tang Group Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of Tianjin Pharmaceutical Da Ren Tang Group's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


Tianjin Pharmaceutical Da Ren Tang Group Business Description

Traded in Other Exchanges
Address
No. 17 Baidi Road, Zhong Xin Mansion, Nankai District, Tianjin, CHN, 300193
Tianjin Pharmaceutical Da Ren Tang Group Corp Ltd is a pharmaceutical manufacturing company. The company manufactures and sells traditional Chinese medicine, western medicine, and healthcare products in the People's Republic of China. It operates in two segments namely The Chinese Medicine segment and The Western Medicine segment. The Chinese Medicine segment manufactures Chinese pharmaceutical products under brands owned by the group. The Western Medicine segment manufactures western pharmaceutical products through cooperation with foreign companies. The company earns the majority of its revenue from the sale of Chinese pharmaceutical products.

Tianjin Pharmaceutical Da Ren Tang Group Headlines

No Headlines